United Therapeutics Corporation Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount
United Therapeutics Corporation (UTHR) reported Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount · last filed 2025-02-26
- United Therapeutics Corporation equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2023-12-31 was $0.00.
- United Therapeutics Corporation equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2023-09-30 was $0.00.
- United Therapeutics Corporation equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2023-06-30 was $0.00.
- United Therapeutics Corporation equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- United Therapeutics Corporation equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2024 was $0.00.
- United Therapeutics Corporation equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- United Therapeutics Corporation equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2022 was $1.70M, a 26.09% decline from fiscal 2021.
- United Therapeutics Corporation equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2021 was $2.30M, a 74.73% decline from fiscal 2020.
| Period end | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 3 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 6 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 9 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-26 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $0.00 derived: sum of 2 quarters · filed 2025-02-26 | $0.00 derived: sum of 3 quarters · filed 2025-02-26 | $0.00 10-K · filed 2025-02-26 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-01 | $0.00 derived: sum of 2 quarters · filed 2023-11-01 | $0.00 10-Q · filed 2023-11-01 | $0.00 derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-02 | $0.00 10-Q · filed 2023-08-02 | $0.00 derived: sum of 3 quarters · filed 2025-02-26 | $0.00 derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-03 | $0.00 derived: sum of 2 quarters · filed 2025-02-26 | $0.00 derived: sum of 3 quarters · filed 2025-02-26 | $0.00 derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $0.00 derived: sum of 2 quarters · filed 2025-02-26 | $0.00 derived: sum of 3 quarters · filed 2025-02-26 | $1.70M 10-K · filed 2025-02-26 |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-01 | $0.00 derived: sum of 2 quarters · filed 2023-11-01 | $1.70M 10-Q · filed 2023-11-01 | $1.70M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-02 | $1.70M 10-Q · filed 2023-08-02 | $1.70M derived: sum of 3 quarters · filed 2024-02-21 | $1.70M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-03-31 | $1.70M 10-Q · filed 2023-05-03 | $1.70M derived: sum of 2 quarters · filed 2024-02-21 | $1.70M derived: sum of 3 quarters · filed 2024-02-21 | $4.00M derived: sum of 4 quarters · filed 2024-02-21 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $0.00 derived: sum of 2 quarters · filed 2024-02-21 | $2.30M derived: sum of 3 quarters · filed 2024-02-21 | $2.30M 10-K · filed 2024-02-21 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-02 | $2.30M derived: sum of 2 quarters · filed 2022-11-02 | $2.30M 10-Q · filed 2022-11-02 | |
| 2021-06-30 | $2.30M 10-Q · filed 2022-08-03 | $2.30M 10-Q · filed 2022-08-03 | ||
| 2020-12-31 | $9.10M 10-K · filed 2023-02-22 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |